GRAIL to Present at the TD Cowen 46th Annual Health Care Conference
Rhea-AI Summary
GRAIL (Nasdaq: GRAL) said company management will present at the TD Cowen 46th Annual Health Care Conference in Boston on Mar. 3, 2026 at 10:30 a.m. ET.
Live and replay webcasts will be available via the company's investor relations website and archived for at least 30 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction – GRAL
In the Feb 25 session, GRAL gained 2.86%, reflecting a moderate positive market reaction. Argus tracked a peak move of +19.1% during that session. Our momentum scanner triggered 88 alerts that day, indicating high trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 19 | Earnings update | Neutral | -3.2% | Reported 2025 results with revenue growth but sizable net losses and cash runway. |
| Feb 19 | Clinical trial data | Neutral | -3.2% | Released NHS-Galleri topline data with mixed endpoint outcome and detection benefits. |
| Jan 29 | Regulatory submission | Positive | -3.1% | Submitted final PMA module to FDA for Galleri multi-cancer early detection test. |
| Dec 15 | Conference presentation | Neutral | -4.4% | Planned corporate update at the 44th Annual J.P. Morgan Healthcare Conference. |
| Dec 01 | Equity compensation | Neutral | -0.9% | Announced inducement RSU grants to recent hires under Nasdaq Listing Rule 5635(c)(4). |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Across the last five news events, GRAL’s shares showed negative next-day reactions to both clinical, earnings, and routine corporate updates, suggesting a pattern of selling into news.
Recent GRAL news highlighted execution and pipeline progress. On Feb 19, 2026, the company reported Q4 and full-year 2025 results with $147.2M revenue and a narrowed net loss, alongside completion of its Galleri PMA submission and landmark NHS-Galleri data; the stock fell about 3%. Earlier in Jan 2026, GRAL announced the FDA PMA submission for Galleri, also followed by a modest decline. Even routine items like a J.P. Morgan conference presentation and inducement grants in late 2025 saw small negative reactions, framing today’s conference announcement in a pattern of post-news weakness.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event.
About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in
For more information, visit grail.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-to-present-at-the-td-cowen-46th-annual-health-care-conference-302696206.html
SOURCE GRAIL, Inc.